Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Luminal B
Interventions: DRUG: Durvalumab|RADIATION: Stereotactic Body Radiotherapy|DRUG: Oleclumab
Sponsor: Jules Bordet Institute
Collaborators: Institut Curie|AstraZeneca